Towards Healthcare
New Chemical Entities (NCE) CDMO Market
Updated Date: 10 October 2025   |   Report Code: 6292
sales@towardshealthcare.com +1 804-441-9344
Download Sample Order Now

New Chemical Entities (NCE) CDMO Market Rising Outsourcing and Advanced Manufacturing

According to market projections, the new chemical entities (NCE) CDMO sector is expected to grow from USD 2.65 billion in 2024 to USD 7.83 billion by 2034, reflecting a CAGR of 11.44%. The new chemical entities (NCE) CDMO market is growing due to its offering hope for managing diseases where existing therapies fall short or are inaccessible. North America is dominant in the market due to increasing pharmaceutical R&D and regulatory support.

Last Updated : 10 October 2025 Category: Healthcare Services Insight Code: 6292 Format: PDF / PPT / Excel

Content

TOC is not Available for this Report

FAQ's

Answer : The new chemical entities (NCE) CDMO market stands at USD 2.95 billion in 2025 and is expected to reach USD 7.83 billion by 2034, growing at a CAGR of 11.44% from 2024 to 2034.

Answer : North America is currently leading the new chemical entities (NCE) CDMO market due to a vast manufacturing capacity and government support.

Answer : A New Chemical Entity (NCE) is a term used in the pharmaceutical industry to describe a compound that emerges from the process of drug discovery. This compound is unique in that it represents a novel structure that has never before been approved for medical use by any regulatory authority around the world.

Answer : Ministry of Health and Family Welfare, FDA, WHO, PIB, CDC.
Any Questions

Meet the Team

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services.

Learn more about Deepa Pandey

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar